Maria E Goossens1, Frank Buntinx1,2, Maurice P Zeegers3, J H M Driessen4,5,6, Marie L De Bruin4, Frank De Vries4,5,6,7. 1. Department of General Practice, KU Leuven, Leuven, Belgium. 2. Department of General Practice, University of Maastricht, Maastricht. 3. NUTRIM School of Nutrition, Metabolism and Toxicology, University of Maastricht, Maastricht. 4. Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht. 5. Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht. 6. Research Institute CAPHRI, University of Maastricht, the Netherlands. 7. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
Abstract
AIM: The aim of this study was to look at the influence of metformin intake and duration, on urinary bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new user design (inception cohort). METHODS: We conducted a retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) including all patients with at least one prescription of oral anti-diabetic drugs (ADD) and/or insulin. The risk of UBC in different groups of ADD users (metformin alone (one), metformin in combination (two) with other ADD medication (glinides, glitazones, DPP-4-inhibitors, SUs, insulin or more than one combination), all metformin users (1 + 2) was compared with SU only users using Cox proportional hazards models. The estimates were adjusted for age, gender, smoking status, BMI and diabetes duration. RESULTS: The inception cohort included 165,398 participants of whom 132,960 were metformin users and 32,438 were SU only users. During a mean follow-up time of more than 5 years 693 patients developed UBC, 124 of the control group and 461 of the all metformin users. There was no association between metformin use and UBC risk (HR = 1.12, 95% CI 0.90, 1.40) compared with SU only users, even after adjustment for diabetes duration (HR = 1.13, 95% CI 0.90, 1.40). We found a pattern of decreasing risk of UBC with increasing duration of metformin intake, which was statistically not significant. CONCLUSION: Metformin has no influence on the risk of UBC compared with SU in type 2 diabetes patients using a new user design.
AIM: The aim of this study was to look at the influence of metformin intake and duration, on urinary bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new user design (inception cohort). METHODS: We conducted a retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) including all patients with at least one prescription of oral anti-diabetic drugs (ADD) and/or insulin. The risk of UBC in different groups of ADD users (metformin alone (one), metformin in combination (two) with other ADD medication (glinides, glitazones, DPP-4-inhibitors, SUs, insulin or more than one combination), all metformin users (1 + 2) was compared with SU only users using Cox proportional hazards models. The estimates were adjusted for age, gender, smoking status, BMI and diabetes duration. RESULTS: The inception cohort included 165,398 participants of whom 132,960 were metformin users and 32,438 were SU only users. During a mean follow-up time of more than 5 years 693 patients developed UBC, 124 of the control group and 461 of the all metformin users. There was no association between metformin use and UBC risk (HR = 1.12, 95% CI 0.90, 1.40) compared with SU only users, even after adjustment for diabetes duration (HR = 1.13, 95% CI 0.90, 1.40). We found a pattern of decreasing risk of UBC with increasing duration of metformin intake, which was statistically not significant. CONCLUSION:Metformin has no influence on the risk of UBC compared with SU in type 2 diabetespatients using a new user design.
Authors: R J Stevens; R Ali; C R Bankhead; M A Bethel; B J Cairns; R P Camisasca; F L Crowe; A J Farmer; S Harrison; J A Hirst; P Home; S E Kahn; J H McLellan; R Perera; A Plüddemann; A Ramachandran; N W Roberts; P W Rose; A Schweizer; G Viberti; R R Holman Journal: Diabetologia Date: 2012-08-10 Impact factor: 10.122
Authors: Monica Franciosi; Giuseppe Lucisano; Emanuela Lapice; Giovanni F M Strippoli; Fabio Pellegrini; Antonio Nicolucci Journal: PLoS One Date: 2013-08-02 Impact factor: 3.240
Authors: Maria E Goossens; Frank Buntinx; Maurice P Zeegers; J H M Driessen; Marie L De Bruin; Frank De Vries Journal: Br J Clin Pharmacol Date: 2015-10-28 Impact factor: 4.335
Authors: Maria E Goossens; Marc Van den Bulcke; Thierry Gevaert; Lydie Meheus; Dirk Verellen; Jean-Marc Cosset; Guy Storme Journal: Ecancermedicalscience Date: 2019-12-09